Since 1974, methicillin-resistant Staphylococcus aureus has emerged as both a nosocomial and a communityacquired pathogen in the United States. These strains have become established hospital flora, with infections caused by methicillin-resistant S. aureus becoming increasingly prevalent (13, 16) . Vancomycin (VM) hydrochloride is generally effective in the treatment of infections involving methicillinresistant S. aureus, although poor clinical responses have been observed, perhaps caused by the tolerance of S. aureus to VM (5, 7, 15) . The combination of trimethoprim (TMP)-sulfamethoxazole (SMX) has been reported to be active in vitro against these resistant strains, although only a limited number of isolates have been examined. In addition, several anecdotal reports suggest that TMP-SMX is valuable in the treatment of S. aureus infections unresponsive to seemingly adequate antibiotic treatment (2, 4, 12, 15 Gavan and Barry (6) . Briefly, fresh bacterial suspensions were made in Wellcotest broth (Burroughs Wellcome Co.) supplemented with NaCl (2%) from overnight cultures and adjusted to a 0.5
McFarland turbidity standard to contain 108 CFU/ml. Wellcotest broth is a thymidine-free, all-purpose bacteriological growth medium. Twofold dilutions of antimicrobial agents, performed with a semiautomated microtiter system * Corresponding author.
by using Wellcotest broth supplemented with NaCl (2%) (Dynatech Laboratories, Inc., Alexandria, Va.), were inoculated with 0.010 ml of a 1:16 dilution of the bacterial suspension for a final concentration of >5 x 105 CFU/ml. All plates were incubated at 30°C for 48 h. The MIC was defined as the lowest concentration of the antibiotic that prevented visible growth. MBC determinations were performed by subculturing 0.010-ml samples from wells showing no visible growth and incubating them for 48 h at 30°C. The MBC was defined as the lowest antibiotic concentration showing -99.9% killing of the initial bacterial inoculum at 48 h (1). Parallel tests were performed with a lower-salt medium (0.1% NaCl) and a higher incubation temperature (37°C) as independent variables.
The MICs and MBCs of VM, TMP, SMX, and TMP-SMX (1:20 fixed ratio) for the 16 S. aureus strains examined in this study are shown in Table 1 . VM demonstrated good in vitro activity against all strains of methicillin-resistant S. aureus, as did TMP. In contrast, SMX showed relatively poor in vitro activity against these isolates (MICs = 50 jxg/ml for 13 of 16 strains). These data support those of Seligman (14), who found that all of the 47 strains of methicillin-resistant S. aureus that he examined were resistant to >64 ,ug of SMX per ml. In addition, VM, TMP, and TMP-SMX showed excellent bactericidal activity against these isolates. For all organisms tested, the MBC was no more than twofold greater than the MIC (Table 1) . Duplicate tests, using a lower NaCl concentration (0.1%) in the growth medium and a higher incubation temperature (37°C), showed virtually identical MIC and MBC results (data not shown).
The definition of synergy is dependent on methodology and to some degree is quite arbitrary ( ) and randomized to treatment groups. Inocula were standardized to produce 90 to 100% mortality in vehicle-treated mice in 72 h. Serial twofold dilutions of TMP, SMX, and the conibination of TMP-SMX (at the 1:5 ratio used clinically) were administered orally to groups of 10 mice each at 1, 3, and 5 h postinfection. Individual 50% effective dose (ED50) values were calculated from the number of mice surviving for 4 days by probit analysis using Litchfield's correction for groups with 100 or 0% survival (9); subsequent analyses were performed on sets of three such values obtained from the replicate studies. The results of these studies are presented in Table 2 . Consistent with the in vitro results, TMP alone was more active against the methicillin-resistant S. aureus isolates tested than SMX alone was. In addition, treatment with the TMP-SMX combination resulted in significantly improved therapeutic activity as evidenced by a five-to sixfold reduction in TMP ED50s. The magnitude of this improved activity suggests that the combination of TMP-SMX is synergistic in vivo.
This study confirmed and extended a previous observation (14) that TMP-SMX is an effective combination against methicillin-resistant S. aureus in vitro. Importantly, the 16 strains of methicillin-resistant S. aureus examined here represented independent, geographically distinct isolates rather than a single isolate possibly spread by cross infection in a single institution. TMP-SMX proved to be an effective combination in vitro against these strains, showing bactericidal activity at the MIC (or twofold higher It should be noted that attainable levels of TMP-SMX in human plasma exceed the MICs and MBCs of the combination for the methicillin-resistant S. aureus isolates reported in this study (Table 1) . For example, a single oral administration of the equivalent of 160 mg of TMP-800 mg of SMX resulted in mean peak blood levels (1 to 4 h after administration) of 1.2 to 1.9 ,ug of TMP and 25 to 60 ,ug of non-protein-bound SMX per ml in healthy adult volunteers (8) 
